Recent Updates
Recently added Catalysts

MK2295

Phase 2

Pain, Postoperative | Small molecule | Pain |Merck & Company, Inc.|Last Updated: Nov 2, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment89
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00387140A Study to Evaluate the Safety and Efficacy of an Investigational Drug in the Treatment of Postoperative Dental Pain (MK-2295-005)PHASE2 COMPLETED 89Oct 1, 2006May 1, 2007Nov 2, 2015 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Peak analgesic response, safety, and tolerability
Over 24 Hours
Secondary Endpoints
Onset of analgesia, duration of analgesia
Over 24 Hours
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
MK2295DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexMALE
Healthy VolunteersYes

Inclusion Criteria: * Patients in generally good health who are scheduled to have two or more third molars removed, at least one of which is partially or completely embedded in bone and is a mandibular impaction Exclusion Criteria: * Patient has a temperature of 37.5C or greater prior to dosing *...

Unlock Eligibility Criteria